Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease

Stephanie Williams, MD, Rama Nanah, MD, Darci Zblewski, CNP, Michelle Elliott, MD, William J. Hogan, MBChB, Raoul Tibes, MD PhD, James M. Foran, MD, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2016) 128 (22): 2799.

https://doi.org/10.1182/blood.V128.22.2799.2799

Published: 2016

Journal Articles

Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates

Ryan D. Gentzler, MD, MS, Andrew M. Evens, DO, MSc, Alfred W. Rademaker, PhD, Bharat B Mittal, M.D., Adam M. Petrich, MD, Jessica K. Altman, MD, Olga Frankfurt, MD, Daina Variakojis, MD, Seema Singhal, M.D., Jayesh Mehta, MD, Joel R Green, MD, Stephanie Williams, MD, Lynne Kaminer, MD, Leo I. Gordon, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2024.

https://doi.org/10.1182/blood.V120.21.2024.2024

Published: 2012

Journal Articles

Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).

Andrew M. Evens, DO, MS, Jane N. Winter, MD, Nanjiang Hou, MS, Fred Rademaker, PhD, Katalin Kelemen, MD, Beverly Nelson, MD, David Patton, BS, Olga Frankfurt, MD, Stephanie Williams, MD, Seema Singhal, MD, Martin S. Tallman, MD, Steven T. Rosen, MD, Jayesh Mehta, MD, Leo I. Gordon, MD

Blood (2006) 108 (11): 2448.

https://doi.org/10.1182/blood.V108.11.2448.2448

Published: 2006

Journal Articles

Autologous Stem Cell Transplantation (AuSCT) with Total Lymphoid Irradiation (TLI) and High-Dose Chemotherapy (CT) Results in High Survival Rates for “Poor-Prognosis” Relapsed/Refractory (R/R) Hodgkin’s Disease (HD): Multivariate Analysis of Outcome Shows Marked Benefit for TLI in a Prospective Phase I/II Trial.

Andrew M. Evens, DO, MS, Alfred Rademaker, PhD, Bharat B. Mittal, MD, Jessica K. Altman, MD, David Patton, BS, Lynne Kaminer, MD, Seema Singhal, MD, Daina Variakojis, MD, Stephanie Williams, MD, Martin S. Tallman, MD, Jayesh N. Mehta, MD, Jane N. Winter, MD, Leo I. Gordon, MD

Blood (2005) 106 (11): 2080.

https://doi.org/10.1182/blood.V106.11.2080.2080

Published: 2005

Journal Articles

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Azra Raza, MD, Natalie Callander, MD, Leonel Ochoa, MD, Lawrence Piro, MD, Peter Emanuel, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Howard Burris, III, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Curtain, MD, Richard Larson, MD, Shelby Young, RN, Gail L. Brown, MD

Blood (2005) 106 (11): 2520.

https://doi.org/10.1182/blood.V106.11.2520.2520

Published: 2005

Journal Articles

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Natalie Callander, MD, Jose L. Ochoa-Bayona, MD, Lawrence Piro, MD, Susan Guba, MD, Gabriel Shapiro, MD, Stephanie Williams, MD, Ira Oliff, MD, Howard Burris, III, MD, Anneliese Jameson, Kiran Patel, Gail L. Brown, MD, Stefan Faderl, MD, Zeev Estrov, MD, Peter Emanuel, MD

Blood (2004) 104 (11): 1428.

https://doi.org/10.1182/blood.V104.11.1428.1428

Published: 2004

NARROW

Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease

Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates

Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Email alerts

ASH Publications

American Society of Hematology

Deficiency of Current Acute Myeloid Leukemia (AML) Response Criteria to Predict Response to Hypomethylating Agent Therapy: The Value of Long-Lasting Stable Disease

Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates

Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).

Hematologic Improvement (HI) by TLK199 (Telintra™), a Novel Glutathione Analog, in Myelodysplastic Syndrome: Phase 2 Study Results.

Hematologic Improvement Following Treatment with TLK199 (Telintra™), a Novel Glutathione Analog Inhibitor of GST P1-1, in Myelodysplastic Syndrome (MDS): Interim Results of a Dose-Ranging Phase 2a Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only